Full Press Release Details
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA.
IRD
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
Key Takeaway: Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy